Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy
DOI:
https://doi.org/10.33393/grhta.2025.3458Keywords:
Atopic dermatitis, Cost per responder, EASI90, EASI100, EASI90 & WP-NRS 0/1, UpadacitinibAbstract
Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib (Upa) 30 mg and dupilumab (Dup) 300 mg in patients with moderate-to-severe atopic dermatitis in Italy.
Methods: A cost per responder analysis was developed based on results of Heads Up, a head-to-head randomized clinical trial. The primary endpoint was EASI75 at week 16, and the secondary endpoints were EASI90, EASI100, and WP-NRS improvement ≥4 points at week 16. The analysis also assessed a fifth exploratory endpoint from a Heads Up post-hoc analysis: EASI90 & WP-NRS 0/1 at week 16. The cost per responder was based on the perspective of the Italian National Health System (I-NHS). Ex-factory prices were used, excluding mandatory and other hidden discounts. The treatment cost was based on the number of administrations at week 16. The cost per responder was adopted as a cost-effectiveness indicator.
Results: Independently of the endpoint evaluated, upadacitinib always had the lower cost per responder than dupilumab. In the base case, the cost-effectiveness of upadacitinib ranges from a minimum of €361.50 considering EASI75 index at week 16 (Upa: €8,839.78 vs. Dup: €9,201.28) to a maximum of €50,376.18 considering EASI100 index at week 16 (Upa: €22,535.2 vs. Dup: €72,911.39). The difference in cost per responder between upadacitinib and dupilumab increased with higher EASI response levels.
Conclusion: Considering five clinical endpoints, the cost per responder for upadacitinib 30 mg was always lower than for dupilumab 300 mg, highlighting its substantial clinical and economic benefits for patients with moderate-to-severe atopic dermatitis.
Downloads
References
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https://doi.org/10.1038/s41572-018-0001-z PMID:29930242 DOI: https://doi.org/10.1038/s41572-018-0001-z
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. https://doi.org/10.1016/S0140-6736(20)31286-1 PMID:32738956 DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017;38(1):3-8. https://doi.org/10.2500/aap.2017.38.4005 PMID:28052794 DOI: https://doi.org/10.2500/aap.2017.38.4005
Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448-456.e30. https://doi.org/10.1016/j.jaad.2018.03.017 PMID:30119868 DOI: https://doi.org/10.1016/j.jaad.2018.03.017
Migliavaca CB, Lazzarini R, Stein C, et al. Prevalence of Atopic Dermatitis: A Systematic Review and Meta-Analysis. Dermatitis. 2024; https://doi.org/10.1089/derm.2024.0165 PMID:39134072 DOI: https://doi.org/10.1089/derm.2024.0165
Neri I, Galeone C, Pelucchi C, et al. Atopic Dermatitis in Italian Pre-School Children: Literature Review of Epidemiological Data with a Focus on Disease Prevalence and Severity. Children (Basel). 2023;10(10):1629. https://doi.org/10.3390/children10101629 PMID:37892292 DOI: https://doi.org/10.3390/children10101629
Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284-1293. https://doi.org/10.1111/all.13401 PMID:29319189 DOI: https://doi.org/10.1111/all.13401
Calzavara Pinton P, Cristaudo A, Foti C, et al. Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA). G Ital Dermatol Venereol. 2018;153(2):133-145. PMID:29237258 DOI: https://doi.org/10.23736/S0392-0488.17.05892-8
EMA. Riassunto delle caratteristiche di prodotto Rinvoq. Online https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_it.pdf (Accessed January 2025)
EMA. Riassunto delle caratteristiche di prodotto Dupixent. Online https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_it.pdf (Accessed January 2025)
Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021;157(9):1047-1055. https://doi.org/10.1001/jamadermatol.2021.3023 PMID:34347860 DOI: https://doi.org/10.1001/jamadermatol.2021.3023
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica. 1980;60(92):44-47. https://doi.org/10.2340/00015555924447 DOI: https://doi.org/10.2340/00015555924447
Eric L Simpson, Antonio Costanzo, Vimal H Prajapati, Brian M Calimlim, Alvina D Chu, Tianshuang Wu, Kilian Eyerich. 528 - Rapid skin clearance and itch improvement with upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3b head-to-head clinical trial (Heads Up). British Journal of Dermatology, Volume 190, Issue Supplement_2, February 2024, Pages ii30–ii31, https://doi.org/10.1093/bjd/ljad498.033 DOI: https://doi.org/10.1093/bjd/ljad498.033
Determinazione AIFA del 3 luglio 2006, GU n 156 del 7 luglio 2006, e successiva Determinazione AIFA del 9 febbraio 2007, GU no 57 del 9 marzo 2007 e proroghe. Online https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2006-07-07&atto.codiceRedazionale=06A06166 (Accessed January 2025)
AGENZIA ITALIANA DEL FARMACODETERMINA 16 maggio 2024 Regime di rimborsabilita' e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano «Rinvoq». (Determina n. 16/2024). (24A02550) (GU Serie Generale n.118 del 22-05-2024). Online https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2024-05-22&atto.codiceRedazionale=24A02550&elenco30giorni=false (Accessed January 2025)
AGENZIA ITALIANA DEL FARMACODETERMINA 8 febbraio 2022 Regime di rimborsabilita' e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano «Dupixent». (Determina n. 116/2022). (22A01100) (GU Serie Generale n.42 del 19-02-2022). Online https://www.gazzettaufficiale.it/eli/id/2022/02/19/22A01100/SG (Accessed January 2025)
Fattore G. Gruppo di lavoro AIES (coordinato da G. Fattore).Proposta di linee guida per la valutazione economica de-gli interventi sanitari in Italia. PharmacoEcon Ital Res Artic. 2009;11(2):83-93. https://doi.org/10.1007/BF03320660 DOI: https://doi.org/10.1007/BF03320660
National Institute for Health and Care Excellence. Guide tothe methods of technology appraisal. 2013. Online https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (Accessed January 2025)
Canadian Agency for Drugs and Technologies in Health. Guide-lines for the Economic Evaluation of Health Technologies: Can-ada, 3rd Edition. 2006. Online https://www.cda-amc.ca/media/pdf/186_EconomicGuidelines_e.pdf (Accessed January 2025)
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2025-02-18
Published 2025-03-10
